[ad_1] Bryan Glass, President of Ranger Gold Corp. (OTC:RNGC), recently acquired additional shares of the company. On December 27, Glass purchased 60,645 shares of common stock at a price of $0.0001 per share, amounting to a total investment of $6. According to InvestingPro data, the stock has shown remarkable performance, with a 1,400% return over the past year, despite experiencing high price volatility. Following this transaction, Glass holds a total of 200,160,645 shares directly. InvestingPro analysis reveals the company is currently not profitable over the last twelve months, with negative earnings per share. This move signifies Glass’s continued involvement and…
Author: user
[ad_1] Eugene S. Stark, Vice President of Administration, Chief Compliance Officer, and Principal Financial (NASDAQ:) Officer at General American Investors Co Inc (NYSE:GAM), recently purchased additional shares of the company’s 5.95% Preferred Stock. The transactions, disclosed in a recent SEC filing, involved the acquisition of 500 shares at a price of $25 each, totaling $12,500. The purchase comes as GAM maintains a strong dividend track record, having paid dividends for 53 consecutive years. According to InvestingPro data, the company currently offers an attractive dividend yield of 8.8%. The purchases were made on December 30 and included 250 shares acquired directly…
[ad_1] Bitcoin was far and away the best performing asset class in 2024 as new ETFs ushered in more widespread adoption and hopes for deregulation under a new presidential administration lifted digital assets to record levels.But owning cryptocurrency also came with its usual unpredictability and dizzying swings, as this month’s trading clearly illustrates. Bitcoin has more than doubled in price since starting the year in the $40,000 range, with it last trading near $95,500. Ether has scored a nearly 50% year-to-date gain, and last traded at around the $3,400 level.Stock Chart IconStock chart iconBitcoin and ether since the start of…
[ad_1] Lytus Technologies Holdings Ptv stock has reached a new 52-week low, trading at $0.84, marking a significant downturn for the company within the past year. According to InvestingPro data, the stock appears undervalued, with a P/E ratio of 6.76 and a price-to-book ratio of just 0.12, while technical indicators suggest oversold conditions. This latest price level reflects a stark contrast to its performance over the last 12 months, with the stock experiencing a precipitous decline of -87.09%. Investors are closely monitoring the company’s movements as it navigates through a challenging period, with market sentiment reflecting the substantial decrease in…
[ad_1] Retail investors enjoyed another banner year by sticking with tried-and-true large-cap tech names that raked in big profits and promised advances in artificial intelligence. Vanda Research estimated the year will end with about $265 billion in net new inflows into US markets by self-directed retail investors. While that is $25 billion less than the previous three years’ average, based on Vanda Research’s data, it’s still within the post-COVID-19 range — indicating a healthy appetite for the average investor to be engaged with markets. The six corporate tickers with the most retail investor inflows were a who’s who of tech…
[ad_1] KUALA LUMPUR: LYC Healthcare Bhd (LYC) has announced plans to list its subsidiary, LYC Healthcare (Cayman) Ltd (LYC Cayman), on the Nasdaq Capital Market. In a Bursa Malaysia filing today, the healthcare company said that LYC Cayman plans to undertake an initial public offering (IPO) of new ordinary shares on the Nasdaq. “The offering size is expected to range between US$5 million and US$15 million, subject to the full exercise of the over-allotment option by underwriters. “The IPO price will be at least US$4.00 per share, with shares offered to third-party investors,” it said. Additionally, It said that following…
[ad_1] LONDON–(BUSINESS WIRE)–Regulatory News: Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (NA:PSH) (PSH) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (Jefferies), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the “Shares”): Total (EPA:) Buyback Ticker/s:PSH (LSE); PSHD (LSE); PSH (XAMS)Date of Purchase:31 December 2024Number of Public Shares Purchased:45,737 SharesAverage Price Paid Per Share:48.62 USD Buyback Breakdown by Trading Venue Trading Venue: London Stock Exchange (LON:)Ticker:PSHDate of Purchase:31 December 2024Number of Public Shares Purchased:34,965 SharesHighest Price Paid Per Share:3,910 pence / 49.01 USDLowest Price Paid Per Share:3,816 pence / 47.83…
[ad_1] filadendron / iStock/Getty Images Commitment to Our Readers GOBankingRates’ editorial team is committed to bringing you unbiased reviews and information. We use data-driven methodologies to evaluate financial products and services – our reviews and ratings are not influenced by advertisers. You can read more about our editorial guidelines and our products and services review methodology. 20 YearsHelping You Live Richer Trusted by Millions of Readers One of the fastest ways to grow your money is to make sure it is doing the earning for you, and not the other way around. If you don’t want to take higher risks…
[ad_1] As 2025 begins, how positive you feel about your finances will depend a lot on the stage of life you have reached. Hopes of sharp interest rate cuts have receded as inflation has started to rise again, which is bad news for borrowers but good news if you have money in the bank. The triple lock means a healthy increase in the state pension in April, while other benefits lag behind. Here are some of the important dates to look out for in the first months of the year.JanuaryEnergy bills will rise in January as the energy price cap…
[ad_1] In a challenging year for Unity Biotechnology Inc (NASDAQ:)., the company’s stock has tumbled to a 52-week low, touching a price level of just $0.94. According to InvestingPro analysis, technical indicators suggest the stock is in oversold territory, with a current market capitalization of just $16.18 million. This latest dip underscores a significant downturn for the biotech firm, which has seen its market value halved over the past year, with a stark 1-year change of -50.26%. While investors have been wary as the company grapples with industry pressures, InvestingPro data shows the company maintains a healthy current ratio of…